PREVALENCE, PATHOGENESIS AND PRINCIPLES OF TREATMENT NONALCOHOLIC FATTY LIVER DISEASE


Cite item

Full Text

Abstract

The article analyzed current data for the prevalence, risk factors, pathogenesis and principles of treatment of nonalcoholic fatty liver disease (NAFLD). It was concluded that NAFLD has a high prevalence in Russian population. The main risk factors for this disease are obesity, type 2 diabetes mellitus, hyperlipidemia, and metabolic syndrome. Currently, non-drug treatments of NAFLD are low-calorie diet with sufficient quantities of polyunsaturated fats and dietary fiber, graduated exercise for weight reduction. Among the drugs, insulin sensitizers, essential phospholipids, ursodeoxycholic acid and antioxidants take a leading position.

References

  1. Alwis de NMW, Day CP. Nonalcoholic fatty liver disease: the mist gradually clears. J Hepatology 2008;48(1):104-12.
  2. Feldstein AE. Pathophysiology of fatty liver: implications for treatment. Pathophysiologic Basis for therapy of liver disease. AASLD: Postgraduate course 2007:55-60.
  3. Brunt EM, Tiniakos DG. Pathological features of NASH. Front Biosci 2005;10(4):1221-31.
  4. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55(2):434-38.
  5. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129(1):113-21.
  6. Neuschwander-Tetri B, Caldwell S. Nonalcoholic steatohepatitis: summary of AASLD single topic conference. Hepatology 2003;37(6):1202-19.
  7. Цуканов В.В, Тонких Ю.Л, Каспаров Э.В. и др. Неалкогольная жировая болезнь печени у взрослого городского населения России (распространенность и факторы риска) // Врач. 2010. № 9. C. 2-6.
  8. Bellentani S, Pozzato G, et al. Clinical course and risk factors of hepatitis C virus related disease in the general population: report from the Dionysos study. Gut 1999;44(3):874-80.
  9. McClain CJ, Barve S, Deaciuc I. Good fat / bad fat. Hepatology 2007;45(6):1343-46.
  10. Tilg H, Hotamisligil CS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006;131(3):934-45.
  11. Bouchier-Hayes L, Lartigue L, Newmeyer DD. Mitochondria: pharmacological manipulation of cell death. J Clin Invest 2005;115(10):2640-47.
  12. Ricci JE, Waterhouse N, Green DR. Mitochondrial functions during cell death, a complex (I-V) dilemma. Cell Death Differ 2003;10(5):488-92.
  13. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004;40(1):185-94.
  14. Mari M, Caballero F, Colell A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006;4(3):185-98.
  15. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in non-alcoholic steatohepatitis. Hepatology 2003;37(4):909-16.
  16. Targher G, Bertolini L, Scala L, et al. Non alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in nondiabetic men. Role of visceral adipose tissue. Diabet Med 2005;22(10):1354-58.
  17. Ueno T, Sugawara S, Sujaku K, et al. Therapeutic effects of diet and exercise in obese patients with fatty liver. J Hepatol 1997;27(1):103-07.
  18. Dixon J, Bhathal P, Hughes N, et al. Improvement in liver histological analysis with weight loss. Hepatology 2004;39(6):1647-54.
  19. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in non-alcoholic fatty liver disease. Am J Gastroenterol 2005;100(5):1082-90.
  20. Belfort R, Harrison SA, Brown K, et al. A placebo controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis. N Engl J Med 2006;355(22):2297-307.
  21. Rakoski MO, Singal AG, Rogers MA, et al. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2010;32(10):1211-21.
  22. Tsukanov VV, Tonkikh JL, Bronnicova EP. Increas of phosphatidylcholine in blood serum was associated with clinical dynamics in patients with NASH as a result of treatment with polyunsaturated phosphatidilcholine and metformin. J Hepatol 2011;54(Suppl.):S347.
  23. Andreone P, Brisc MC, Chiaramonte M, et al. Silybin conjugated with phosphatidilcholine and vitamin E improves liver damage in patients with NAFLD: the results of a randomized multicentre double-blind vs. placebo trial. J Hepatol 2011;54(Suppl.):S330-S331.
  24. Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008;40(3):194-99.
  25. Ratzui V, De Ledinghen V, Oberti F, et al. A randomized controlled trial of high-dosei ursodeoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011;54(5):1011-19.
  26. Leuschner UF, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52(2):472-79.
  27. Haedrich M, Dufour JF. UDCA for NASH: End of the story? J Hepatol 2011;54(5):856-58.
  28. Lavine J. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000;136(6):734-38.
  29. Abdelmalek M, Angulo P, Jorgensen R, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96(9):2711-17.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies